Correction to: Blood Cancer Journal https://doi.org/10.1038/s41408-018-0119-y, published online 22 August 2018
It came to the author’s attention that the conflict of interest statement is incomplete, the revised COI statement is as follows:
Conflict of interest
H.O. and T.H. declare that they have no conflict of interest. K.C.A. serves on advisory boards for Celgene, Millennium, and Gilead Sciences, and is a scientific founder with financial interest in Acetylon, OncoPep, and C4 Therapeutics.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ohguchi, H., Hideshima, T. & Anderson, K.C. Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer J. 11, 165 (2021). https://doi.org/10.1038/s41408-021-00559-4
Published:
DOI: https://doi.org/10.1038/s41408-021-00559-4
